Your browser doesn't support javascript.
loading
Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report.
Wang, Zhan; Geng, Yan; Yuan, Ling-Yan; Wang, Miao-Miao; Ye, Chen-Yang; Sun, Li; Dai, Wei-Ping; Zang, Yuan-Sheng.
Afiliação
  • Wang Z; Department of Medical Oncology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
  • Geng Y; Department of Nursing, Shanghai Jing'an District Zhabei Central Hospital, Shanghai, China.
  • Yuan LY; Department of Medical Oncology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
  • Wang MM; Department of Medical Oncology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
  • Ye CY; Department of Medical Oncology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
  • Sun L; Department of Medical Oncology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
  • Dai WP; Department of Medical Oncology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
  • Zang YS; Department of Medical Oncology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Front Oncol ; 12: 761558, 2022.
Article em En | MEDLINE | ID: mdl-35237506
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China